Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs | The Manila Times
Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologiesCollaboration aims to combine best-in-class PCIOL optics with first-in-class platform to enable fine-tuning of visual outcomes after cataract surgery ALISO VIEJO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).
Ähnliche Seiten
Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor | The Manila Times
https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/praxis-precision-medicines-and-remagine-labs-announce-strategic-collaboration-to-develop-transdermal-ulixacaltamide-for-essential-tremor/2379853RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement | The Manila Times
https://www.manilatimes.net/2026/07/07/tmt-newswire/globenewswire/rxsight-inc-announces-preliminary-second-quarter-financial-results-and-product-pipeline-updates-following-strategic-collaboration-agreement/2379362
Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science | The Manila Times
https://www.manilatimes.net/2026/05/26/tmt-newswire/pr-newswire/insilico-medicine-and-human-longevity-announce-collaboration-to-co-develop-industry-first-ai-foundation-model-for-longevity-science/2351874Vect-Horus announces collaboration and license option agreement with Servier to develop targeted oligonucleotide therapeutics for rare CNS diseases | The Manila Times
https://www.manilatimes.net/2026/06/30/tmt-newswire/globenewswire/vect-horus-announces-collaboration-and-license-option-agreement-with-servier-to-develop-targeted-oligonucleotide-therapeutics-for-rare-cns-diseases/2375405Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis | The Manila Times
https://www.manilatimes.net/2026/06/12/tmt-newswire/pr-newswire/simcere-pharmaceutical-enters-into-a-research-collaboration-agreement-with-stanford-medicine-to-develop-innovative-therapies-for-patients-with-idiopathic-pulmonary-fibrosis/2364238